Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CLDN18.2 expression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

CLDN18.2 expression	Endometrial Cancer	CLDN18.2 expression	Endometrial Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical Clin Cancer Res - 1 week (New D) CLDN18.2-targeted antibody-drug conjugate Sensitive : D Clin Cancer Res - 1wk	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical Clin Cancer Res - 1 week CLDN18.2-targeted antibody-drug conjugate Sensitive : D Clin Cancer Res - 1 week - (New D)
CLDN18.2 expression	Ovarian Cancer	CLDN18.2 expression	Ovarian Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical Clin Cancer Res - 1 week (New D) CLDN18.2-targeted antibody-drug conjugate Sensitive : D Clin Cancer Res - 1wk	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical Clin Cancer Res - 1 week CLDN18.2-targeted antibody-drug conjugate Sensitive : D Clin Cancer Res - 1 week - (New D)
CLDN18.2 expression	Lung Adenocarcinoma	CLDN18.2 expression	Lung Adenocarcinoma	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks (New D) SOT102 Sensitive : D ESMO-TAT 2023 - 2wk	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks SOT102 Sensitive : D ESMO-TAT 2023 - 2 weeks - (New D)
CLDN18.2 expression	Colon Cancer	CLDN18.2 expression	Colon Cancer	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks (New D) SOT102 Sensitive : D ESMO-TAT 2023 - 2wk	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks SOT102 Sensitive : D ESMO-TAT 2023 - 2 weeks - (New D)
CLDN18.2 expression	Hepatocellular Cancer	CLDN18.2 expression	Hepatocellular Cancer	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks (New D) SOT102 Sensitive : D ESMO-TAT 2023 - 2wk	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks SOT102 Sensitive : D ESMO-TAT 2023 - 2 weeks - (New D)
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks (New D) SOT102 Sensitive : D ESMO-TAT 2023 - 2wk	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks SOT102 Sensitive : D ESMO-TAT 2023 - 2 weeks - (New D)
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks (New D) SOT102 Sensitive : D ESMO-TAT 2023 - 2wk	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks SOT102 Sensitive : D ESMO-TAT 2023 - 2 weeks - (New D)
CLDN18.2 expression	Esophageal Adenocarcinoma	CLDN18.2 expression	Esophageal Adenocarcinoma	IMAB362 Sensitive: C2 – Inclusion Criteria IMAB362 Sensitive : C2	IMAB362 Sensitive: C2 – Inclusion Criteria IMAB362 Sensitive : C2
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	IMAB362 Sensitive: C2 – Inclusion Criteria IMAB362 Sensitive : C2	IMAB362 Sensitive: C2 – Inclusion Criteria IMAB362 Sensitive : C2
CLDN18.2 expression	Gastric Adenocarcinoma	CLDN18.2 expression	Gastric Adenocarcinoma	IMAB362 Sensitive: C2 – Inclusion Criteria IMAB362 Sensitive : C2	IMAB362 Sensitive: C2 – Inclusion Criteria IMAB362 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	Q-1802 Sensitive: C3 – Early Trials Q-1802 Sensitive : C3	Q-1802 Sensitive: C3 – Early Trials Q-1802 Sensitive : C3
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D
CLDN18.2 expression	Solid Tumor	CLDN18.2 expression	Solid Tumor	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D